Ari VanderWalde on Melanoma New Data on Ipilimumab and Nivolumab - The ASCO Post https://t.co/MHinYfgwDN. So great to have had the opportunity to present #S1616 at a plenary session at #AACR2022. Link is to #ASCOPost video.
Combination Immunotherapy Clinical Trials: @arivanderw, @ivanpantic1980, @DrBenTran, and Zev A. Wainberg, MD, explored this topic in a plenary session Tuesday at #AACR22. Read a recap in AACR Meeting News: https://t.co/wJ6JFCtnDb
Patients with advanced melanoma receiving nivolumab plus ipilimumab in the second-line setting had significant improvement in progression-free survival. #AACR22 | @AACR@arivanderw
https://t.co/1dJ5QRzL0o
#mdpijpm e-Book of Special Issue "#Personalized Medicine in #Oncology"
https://t.co/qWfaUl9pii
This Special Issue book was edited by Dr. Ari VanderWalde from West Cancer Center and Research Institute
A NEW Special Issue "Precision Oncology" is guest-edited by Dr. Ari VanderWalde from West Cancer Center and Research Institute https://t.co/rbqFcnSmlD #mdpijpm via @JPM_MDPI#oncology#next-generation sequencing #clinical trials #liquid biopsy